sphingosine-phosphorylcholine and Sjogren-s-Syndrome

sphingosine-phosphorylcholine has been researched along with Sjogren-s-Syndrome* in 1 studies

Other Studies

1 other study(ies) available for sphingosine-phosphorylcholine and Sjogren-s-Syndrome

ArticleYear
Sphingosylphosphorylcholine ameliorates experimental sjögren's syndrome by regulating salivary gland inflammation and hypofunction, and regulatory B cells.
    Immunology letters, 2022, Volume: 248

    Sjögren syndrome (SS) is an autoimmune disease in which immune cells infiltrate the exocrine gland. Since SS is caused by a disorder of the immune system, treatments should regulate the immune response. Sphingosylphosphorylcholine (SPC) is a sphingolipid that mediates cellular signaling. In immune cells, SPC has several immunomodulatory functions. Accordingly, this study verifies the immunomodulatory ability and therapeutic effect of SPC in SS. To understand the function of SPC in SS, we treated SPC in female NOD/ShiJcl (NOD) mice. The mice were monitored for 10 weeks, and inflammation in the salivary glands was checked. After SPC treatment, we detected the expression of regulatory B (B

    Topics: Animals; B-Lymphocytes, Regulatory; Disease Models, Animal; Female; Humans; Inflammation; Mice; Mice, Inbred NOD; Phosphorylcholine; Sialadenitis; Sjogren's Syndrome; Sphingosine

2022